Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity

EBioMedicine

Volumn 3, Issue , 2016, Pages 67-78

  Martins, Karen A O ^a   Cooper, Christopher L ^a   Stronsky, Sabrina M ^a   Norris, Sarah L W ^a   Kwilas, Steven A ^a   Steffens, Jesse T ^a   Benko, Jacqueline G ^a   van Tongeren, Sean A ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Adjuvant; Durable protection; Ebola virus; Immune correlates; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CHEMOKINE RECEPTOR CXCR5; CPG OLIGODEOXYNUCLEOTIDE; INDUCIBLE T CELL COSTIMULATOR LIGAND; PHOSPHORYL LIPID A; PROTEIN BCL 6; TOLL LIKE RECEPTOR AGONIST; VACCINE; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EBOLAVIRUS; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FILOVIRUS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOVIRION NEUTRALIZATION ASSAY; VIRUS LIKE AGENT; ANIMAL; DISEASE MODEL; HEMORRHAGIC FEVER, EBOLA; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; T LYMPHOCYTE SUBPOPULATION;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MODELS, ANIMAL; T-LYMPHOCYTE SUBSETS; VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84958936057     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.11.041     Document Type: Article

References (87)

1. Agnandji S.T., Huttner A., Zinser M.E., Njuguna P., Dahlke C., Fernandes J.F., Yerly S., Dayer J.A., Kraehling V., Kasonta R., Adegnika A.A., Altfeld M., Auderset F., Bache E.B., Biedenkopf N., Borregaard S., Brosnahan J.S., Burrow R., Combescure C., Desmeules J., Eickmann M., Fehling S.K., Finckh A., Goncalves A.R., Grobusch M.P., Hooper J., Jambrecina A., Kabwende A.L., Kaya G., Kimani D., Lell B., Lemaitre B., Lohse A.W., Massinga-Loembe M., Matthey A., Mordmuller B., Nolting A., Ogwang C., Ramharter M., Schmidt-Chanasit J., Schmiedel S., Silvera P., Stahl F.R., Staines H.M., Strecker T., Stubbe H.C., Tsofa B., Zaki S., Fast P., Moorthy V., Kaiser L., Krishna S., Becker S., Kieny M.P., Bejon P., Kremsner P.G., Addo M.M., Siegrist C.A. Phase 1 trials of rVSV ebola vaccine in Africa and Europe - preliminary report. N. Engl. J. Med. 2015, (ePub ahead of print).
2. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappab by Toll-Like receptor 3. Nature 2001, 413:732-738.
3. Audet J., Wong G., Wang H., Lu G., Gao G.F., Kobinger G., Qiu X. Molecular characterization of the monoclonal antibodies composing zmab: a protective cocktail against Ebola virus. Sci. Rep. 2014, 4:6881.
4. Bale S., Dias J.M., Fusco M.L., Hashiguchi T., Wong A.C., Liu T., Keuhne A.I., Li S., Woods V.L., Chandran K., Dye J.M., Saphire E.O. Structural basis for differential neutralization of ebolaviruses. Viruses 2012, 4:447-470.
5. Baumgartner C.K., Malherbe L.P. Regulation of CD4 T-cell receptor diversity by vaccine adjuvants. Immunology 2010, 130:16-22.
6. Beran J. Safety and immunogenicity of a new Hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert. Opin. Biol. Ther. 2008, 8:235-247.
7. Bohannon J.K., Hernandez A., Enkhbaatar P., Adams W.L., Sherwood E.R. The immunobiology of Toll-Like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants. Shock 2013, 40:451-462.
8. Bray M., Davis K., Geisbert T., Schmaljohn C., Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 1998, 178:651-661.
9. Brown D.M., Lee S., Garcia-Hernandez Mde L., Swain S.L. Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J. Virol. 2012, 86:6792-6803.
10. Brunner R., Jensen-Jarolim E., Pali-Scholl I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol. Lett. 2010, 128:29-35.
11. Caproni E., Tritto E., Cortese M., Muzzi A., Mosca F., Monaci E., Baudner B., Seubert A., De Gregorio E. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of Action. J. Immunol. 2012, 188:3088-3098.
12. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
13. Doll K.L., Harty J.T. Correlates of protective immunity following whole sporozoite vaccination against malaria. Immunol. Res. 2014, 59:166-176.
14. Dye J.M., Herbert A.S., Kuehne A.I., Barth J.F., Muhammad M.A., Zak S.E., Ortiz R.A., Prugar L.I., Pratt W.D. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5034-5039.
15. Einstein M.H., Levin M.J., Chatterjee A., Chakhtoura N., Takacs P., Catteau G., Dessy F.J., Moris P., Lin L., Struyf F., Dubin G., Group, H.P.V.S. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through month 48 in a Phase III randomized study. Hum. Vaccines Immunother. 2014, 10:3455-3465.
16. Einstein M.H., Takacs P., Chatterjee A., Sperling R.S., Chakhtoura N., Blatter M.M., Lalezari J., David M.P., Lin L., Struyf F., Dubin G., Group, H.P.V.S. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum. Vaccines Immunother. 2014, 10:3435-3445.
17. Finkelman F.D., Katona I.M., Mosmann T.R., Coffman R.L. IFN-Gamma Regulates the isotypes of Ig secreted during in vivo humoral immune responses. J. Immunol. 1988, 140:1022-1027.
18. Grant-Klein R.J., Altamura L.A., Badger C.V., Bounds C.E., Van Deusen N.M., Kwilas S.A., Vu H.A., Warfield K.L., Hooper J.W., Hannaman D., Dupuy L.C., Schmaljohn C.S. Codon-optimized Filovirus DNA Vaccines Delivered by Intramuscular Electroporation Protect Cynomolgus Macaques from Lethal Ebola and Marburg Virus Challenges. Hum. Vaccines Immunother. 2015, 11(8):1991-2004.
19. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32:155-172.
20. Guven E., Duus K., Laursen I., Hojrup P., Houen G. Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway. PLoS One 2013, 8:e74445.
21. Hanson M.C., Crespo M.P., Abraham W., Moynihan K.D., Szeto G.L., Chen S.H., Melo M.B., Mueller S., Irvine D.J. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J. Clin. Invest. 2015, 125:2532-2546.
22. Hartmann G., Battiany J., Poeck H., Wagner M., Kerkmann M., Lubenow N., Rothenfusser S., Endres S. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 2003, 33:1633-1641.
23. Henao-Tamayo M.I., Ordway D.J., Irwin S.M., Shang S., Shanley C., Orme I.M. Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 2010, 17:618-625.
24. Hikono H., Kohlmeier J.E., Takamura S., Wittmer S.T., Roberts A.D., Woodland D.L. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J. Exp. Med. 2007, 204:1625-1636.
25. Hogenesch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20(Suppl. 3):S34-S39.
26. Hutchison S., Benson R.A., Gibson V.B., Pollock A.H., Garside P., Brewer J.M. Antigen depot is not required for alum adjuvanticity. FASEB J. 2012, 26:1272-1279.
27. Jain S., O'Hagan D.T., Singh M. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev. Vaccines 2011, 10:1731-1742.
28. Johnson S., Eller M., Teigler J.E., Maloveste S.M., Schultz B.T., Soghoian D.Z., Lu R., Oster A.F., Chenine A.L., Alter G., Dittmer U., Marovich M., Robb M.L., Michael N.L., Bolton D., Streeck H. Cooperativity of HIV-specific cytolytic CD4+ T cells and CD8+ T cells in control of HIV viremia. J. Virol. 2015, 89(15):7494-7505.
29. Kastenmuller K., Espinosa D.A., Trager L., Stoyanov C., Salazar A.M., Pokalwar S., Singh S., Dutta S., Ockenhouse C.F., Zavala F., Seder R.A. Full-length P. falciparum circumsporozoite protein administered with poly-ICLC or GLA/SE elicits potent antibody and CD4+ T cell immunity and protection in Mice. Infect. Immun. 2012, 81(3):789-800.
30. Kok T., Gaeguta A., Finnie J., Gorry P.R., Churchill M., Li P. Designer antigens for elicitation of broadly neutralizing antibodies against HIV. Clin. Transl. Immunol. 2014, 3:e24.
31. Krishnan L., Gurnani K., Dicaire C.J., van Faassen H., Zafer A., Kirschning C.J., Sad S., Sprott G.D. Rapid clonal expansion and prolonged maintenance of memory CD8+ T cells of the effector (CD44highCD62Llow) and central (CD44highCD62Lhigh) phenotype by an archaeosome adjuvant independent of TLR2. J. Immunol. 2007, 178:2396-2406.
32. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 454:177-182.
33. Lefrancois L., Masopust D. T cell immunity in lymphoid and non-lymphoid tissues. Curr. Opin. Immunol. 2002, 14:503-508.
34. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadarola M.J., London W.T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132:434-439.
35. Longhi M.P., Trumpfheller C., Idoyaga J., Caskey M., Matos I., Kluger C., Salazar A.M., Colonna M., Steinman R.M. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 2009, 206:1589-1602.
36. Marrack P., Mckee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9:287-293.
37. Marshall J.D., Fearon K., Abbate C., Subramanian S., Yee P., Gregorio J., Coffman R.L., Van Nest G. Identification of a novel cpg DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 2003, 73:781-792.
38. Martins K.A., Steffens J.T., van Tongeren S.A., Wells J.B., Bergeron A.A., Dickson S.P., Dye J.M., Salazar A.M., Bavari S. Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation. PLoS One 2014, 9:e89735.
39. Martins K., Carra J.H., Cooper C.L., Kwilas S.A., Robinson C.G., Shurtleff A.C., Schokman R.D., Kuehl K.A., Wells J.B., Steffens J.T., van Tongeren S.A., Hooper J.W., Bavari S. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein. Viral Immunol. 2015, 28:62-70.
40. Martins K.A., Bavari S., Salazar A.M. Vaccine adjuvant uses of poly-ic and derivatives. Expert Rev. Vaccines 2015, 14:447-459.
41. Marzi A., Engelmann F., Feldmann F., Haberthur K., Shupert W.L., Brining D., Scott D.P., Geisbert T.W., Kawaoka Y., Katze M.G., Feldmann H., Messaoudi I. Antibodies are necessary for rvsv/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1893-1898.
42. McAleer J.P., Vella A.T. Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol. 2010, 31:429-435.
43. McKinstry K.K., Strutt T.M., Kuang Y., Brown D.M., Sell S., Dutton R.W., Swain S.L. Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J. Clin. Invest. 2012, 122:2847-2856.
44. Mendoza D., Migueles S.A., Rood J.E., Peterson B., Johnson S., Doria-Rose N., Schneider D., Rakasz E., Trivett M.T., Trubey C.M., Coalter V., Hallahan C.W., Watkins D., Franchini G., Lifson J.D., Connors M. Cytotoxic capacity of SIV-specific CD8(+) T cells against primary autologous targets correlates with immune control in SIV-infected rhesus macaques. PLoS Pathog. 2013, 9:e1003195.
45. Monaci E., Mancini F., Lofano G., Bacconi M., Tavarini S., Sammicheli C., Arcidiacono L., Giraldi M., Galletti B., Rossi Paccani S., Torre A., Fontana M.R., Grandi G., De Gregorio E., Bensi G., Chiarot E., Nuti S., Bagnoli F., Soldaini E., Bertholet S. MF59- and Al(OH)3-Adjuvanted Staphylococcus aureus (4C-Staph) Vaccines Induce Sustained Protective Humoral and Cellular Immune Responses, with a Critical Role for Effector CD4 T Cells at Low Antibody Titers. Front. Immunol. 2015, 6:439.
46. Moon J.J., Suh H., Li A.V., Ockenhouse C.F., Yadava A., Irvine D.J. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1080-1085.
47. Nemes M.M., Tytell A.A., Lampson G.P., Field A.K., Hilleman M.R. Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Proc. Soc. Exp. Biol. Med. 1969, 132:776-783.
48. O'Hagan D.T., Fox C.B. New generation adjuvants - From empiricism to rational design. Vaccine 2015, 33(Suppl. 2):B14-B20.
49. Olinger G.G., Bailey M.A., Dye J.M., Bakken R., Kuehne A., Kondig J., Wilson J., Hogan R.J., Hart M.K. Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol. 2005, 79:14189-14196.
50. Oswald W.B., Geisbert T.W., Davis K.J., Geisbert J.B., Sullivan N.J., Jahrling P.B., Parren P.W., Burton D.R. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 2007, 3:e9.
51. Perret R., Sierro S.R., Botelho N.K., Corgnac S., Donda A., Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res. 2013, 73:6597-6608.
52. Pitoiset F., Vazquez T., Bellier B. Enveloped virus-like particle platforms: Vaccines of the future?. Expert Rev. Vaccines 2015, 1-3.
53. Plotkin S.A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 2010, 17:1055-1065.
54. Qiu X., Audet J., Wong G., Pillet S., Bello A., Cabral T., Strong J.E., Plummer F., Corbett C.R., Alimonti J.B., Kobinger G.P. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 2012, 4:138ra81.
55. Quinn K.M., Da Costa A., Yamamoto A., Berry D., Lindsay R.W., Darrah P.A., Wang L., Cheng C., Kong W.P., Gall J.G., Nicosia A., Folgori A., Colloca S., Cortese R., Gostick E., Price D.A., Gomez C.E., Esteban M., Wyatt L.S., Moss B., Morgan C., Roederer M., Bailer R.T., Nabel G.J., Koup R.A., Seder R.A. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 2013, 190:2720-2735.
56. Quinn K.M., Yamamoto A., Costa A., Darrah P.A., Lindsay R.W., Hegde S.T., Johnson T.R., Flynn B.J., Lore K., Seder R.A. Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J. Immunol. 2013, 191:5085-5096.
57. Rao M., Bray M., Alving C.R., Jahrling P., Matyas G.R. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J. Virol. 2002, 76:9176-9185.
58. Roy C.J., Brey R.N., Mantis N.J., Mapes K., Pop I.V., Pop L.M., Ruback S., Killeen S.Z., Doyle-Meyers L., Vinet-Oliphant H.S., Didier P.J., Vitetta E.S. Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:3782-3787.
59. Sant A.J., McMichael A. Revealing the role of CD4(+) T cells in viral immunity. J. Exp. Med. 2012, 209:1391-1395.
60. Seder R., Reed S.G., O'Hagan D., Malyala P., D'Oro U., Laera D., Abrignani S., Cerundolo V., Steinman L., Bertholet S. Gaps in knowledge and prospects for research of adjuvanted vaccines. Vaccine 2015, 33(Suppl. 2):B40-B43.
61. Shedlock D.J., Aviles J., Talbott K.T., Wong G., Wu S.J., Villarreal D.O., Myles D.J., Croyle M.A., Yan J., Kobinger G.P., Weiner D.B. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol. Ther. 2013, 21:1432-1444.
62. Snapper C.M., Paul W.E. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987, 236:944-947.
63. Soghoian D.Z., Streeck H. Cytolytic CD4(+) T cells in viral immunity. Expert Rev. Vaccines 2010, 9:1453-1463.
64. Sokolovska A., Hem S.L., Hogenesch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 2007, 25:4575-4585.
65. Sridhar S., Begom S., Bermingham A., Hoschler K., Adamson W., Carman W., Bean T., Barclay W., Deeks J.J., Lalvani A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 2013, 19:1305-1312.
66. Stahl-Hennig C., Eisenblatter M., Jasny E., Rzehak T., Tenner-Racz K., Trumpfheller C., Salazar A.M., Uberla K., Nieto K., Kleinschmidt J., Schulte R., Gissmann L., Muller M., Sacher A., Racz P., Steinman R.M., Uguccioni M., Ignatius R. Synthetic double-stranded rnas are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5:e1000373.
67. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29:3341-3355.
68. Sullivan N.J., Martin J.E., Graham B.S., Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 2009, 7:393-400.
69. Sullivan N.J., Hensley L., Asiedu C., Geisbert T.W., Stanley D., Johnson J., Honko A., Olinger G., Bailey M., Geisbert J.B., Reimann K.A., Bao S., Rao S., Roederer M., Jahrling P.B., Koup R.A., Nabel G.J. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 2011, 17:1128-1131.
70. Surquin M., Tielemans C., Nortier J., Jadoul M., Peeters P., Ryba M., Roznovsky L., Doman J., Barthelemy X., Crasta P.D., Messier M., Houard S. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum. Vaccines 2011, 7:913-918.
71. Swenson D.L., Warfield K.L., Kuehl K., Larsen T., Hevey M.C., Schmaljohn A., Bavari S., Aman M.J. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol. Med. Microbiol. 2004, 40:27-31.
72. Swenson D.L., Warfield K.L., Negley D.L., Schmaljohn A., Aman M.J., Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005, 23:3033-3042.
73. Swenson D.L., Wang D., Luo M., Warfield K.L., Woraratanadharm J., Holman D.H., Dong J.Y., Pratt W.D. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 2008, 15:460-467.
74. Swenson D.L., Warfield K.L., Larsen T., Alves D.A., Coberley S.S., Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev. Vaccines 2008, 7:417-429.
75. Trumpfheller C., Caskey M., Nchinda G., Longhi M.P., Mizenina O., Huang Y., Schlesinger S.J., Colonna M., Steinman R.M. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:2574-2579.
76. van Gils M.J., Sanders R.W. In vivo protection by broadly neutralizing HIV antibodies. Trends Microbiol. 2014, 22:550-551.
77. Verthelyi D., Ishii K.J., Gursel M., Takeshita F., Klinman D.M. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 2001, 166:2372-2377.
78. Wang Y., Cella M., Gilfillan S., Colonna M. Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells. J. Immunol. 2010, 184:2751-2755.
79. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., Aman M.J., Bavari S. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15889-15894.
80. Warfield K.L., Swenson D.L., Negley D.L., Schmaljohn A.L., Aman M.J., Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 2004, 22:3495-3502.
81. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 2007, 196(Suppl. 2):s430-s437.
82. Watkins D.I. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes-a review. Mem. Inst. Oswaldo Cruz 2008, 103:119-129.
83. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., Lambkin-Williams R., Gilbert A., Oxford J., Nicholas B., Staples K.J., Dong T., Douek D.C., Mcmichael A.J., Xu X.N. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 2012, 18:274-280.
84. Wong G., Richardson J.S., Pillet S., Patel A., Qiu X., Alimonti J., Hogan J., Zhang Y., Takada A., Feldmann H., Kobinger G.P. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med. 2012, 4:158ra146.
85. Wong G., Audet J., Fernando L., Fausther-Bovendo H., Alimonti J.B., Kobinger G.P., Qiu X. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014, 32:5722-5729.
86. Zens K.D., Farber D.L. Memory CD4 T cells in influenza. Curr. Top. Microbiol. Immunol. 2015, 386:399-421.
87. Zhou Y., Callendret B., Xu D., Brasky K.M., Feng Z., Hensley L.L., Guedj J., Perelson A.S., Lemon S.M., Lanford R.E., Walker C.M. Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J. Exp. Med. 2012, 209:1481-1492.